CYCN · As filed with the SEC
Korsana Biosciences balance sheet, by quarter
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets (Unaudited) · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 1,391,000 | 2,823,000 | 3,240,000 | 4,568,000 | 3,006,000 | 3,639,000 | 3,232,000 | 2,872,000 |
| Accounts receivable | 0 | 0 | 1,000,000 | 100,000 | 525,000 | 581,000 | 556,000 | 44,000 |
| Prepaid expenses | 112,000 | 255,000 | 384,000 | 386,000 | 462,000 | 256,000 | 421,000 | 621,000 |
| Other current assets | 11,000 | 11,000 | 11,000 | 11,000 | 27,000 | 21,000 | 16,000 | 11,000 |
| Total current assets | 1,514,000 | 3,089,000 | 4,635,000 | 5,065,000 | 4,020,000 | 4,497,000 | 4,225,000 | 3,548,000 |
| Property, Plant and Equipment, Net | 66,000 | 66,000 | — | — | — | — | — | — |
| Other investment | 5,350,000 | 5,350,000 | 5,350,000 | 5,350,000 | 5,350,000 | 5,350,000 | 5,350,000 | 5,350,000 |
| Total assets | 6,930,000 | 8,505,000 | 9,985,000 | 10,415,000 | 9,370,000 | 9,847,000 | 9,575,000 | 8,898,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 1,597,000 | 457,000 | 508,000 | 480,000 | 462,000 | 483,000 | 390,000 | 304,000 |
| Accrued research and development costs | 26,000 | 148,000 | 198,000 | 46,000 | 72,000 | 50,000 | 52,000 | 72,000 |
| Accrued expenses and other current liabilities | 220,000 | 1,109,000 | 194,000 | 351,000 | 266,000 | 534,000 | 283,000 | 324,000 |
| Total current liabilities | 1,843,000 | 1,714,000 | 900,000 | 877,000 | 800,000 | 1,067,000 | 725,000 | 700,000 |
| Commitments and contingencies (Note 6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stockholders' equity | ||||||||
| Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at June 30, 2026 and December 31, 2025 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock, no par value, 400,000,000 shares authorized at June 30, 2026 and December 31, 2025; 4,330,314 and 3,925,314 shares issued at June 30, 2026 and December 31, 2025, respectively; 4,256,284 and 3,821,236 shares outstanding at June 30, 2026 and December 31, 2025, respectively | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Paid-in capital | 281,039,000 | 280,988,000 | 280,105,000 | 279,759,000 | 277,815,000 | 277,701,000 | 276,342,000 | 276,220,000 |
| Accumulated deficit | (275,952,000) | (274,197,000) | (271,020,000) | (270,221,000) | (269,245,000) | (268,921,000) | (267,492,000) | (268,022,000) |
| Accumulated other comprehensive loss | — | — | — | — | — | — | 0 | 0 |
| Total stockholders' equity | 5,087,000 | 6,791,000 | 9,085,000 | 9,538,000 | 8,570,000 | 8,780,000 | 8,850,000 | 8,198,000 |
| Total liabilities and stockholders' equity | 6,930,000 | 8,505,000 | 9,985,000 | 10,415,000 | 9,370,000 | 9,847,000 | 9,575,000 | 8,898,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.